Published in Health Business Week, December 22nd, 2006
Bioclones is owned 49.9% by African Biotechnology Medical Innovation Investments Limited (ABMI) a wholly owned subsidiary of JSE-listed Sekunjalo Investments Limited.
The conclusion of this agreement was made possible by a $5.3 million investment by BioPAD a biotechnology Regional Innovation Centre established by the Department of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.